Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

288 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM. Topol EJ, et al. Among authors: tcheng je. JAMA. 1997 Aug 13;278(6):479-84. doi: 10.1001/jama.278.6.479. JAMA. 1997. PMID: 9256222 Clinical Trial.
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, et al. Harrington RA, et al. Among authors: tcheng je. Am J Cardiol. 1995 Dec 15;76(17):1222-7. doi: 10.1016/s0002-9149(99)80345-2. Am J Cardiol. 1995. PMID: 7503000 Clinical Trial.
An overview of the results of the EPIC trial.
Califf RM, Lincoff AM, Tcheng JE, Topol EJ. Califf RM, et al. Among authors: tcheng je. Eur Heart J. 1995 Nov;16 Suppl L:43-9. doi: 10.1093/eurheartj/16.suppl_l.43. Eur Heart J. 1995. PMID: 8869018 Clinical Trial.
288 results